Misiu: Yes GILD is in deep trouble: - KITE acqu
Post# of 145286
- KITE acquisition has not paid the amount of money they invested.
- They have failed with their candidate for NASH
- TRUVADA is now generic and they need to replace (Descovy).
- Has strong competition in ViiV
- GILD is basically now a single-product company (TAF-based products).
- Has greatly under-invested in HIV research.
The solution: Leronlimab !!!!
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)